“A support network is essential to those living with HAE,” stated Gustav Christensen, President and Chief Executive Officer of Dyax. “These honorees truly exemplify the meaningful difference individuals can make for someone struggling with a rare disease.”In addition to recognizing a group of honorees who have demonstrated extraordinary commitment to a specific HAE patient or the HAE community in general, the goal of the HAE Allies program is to utilize insights from the submissions to empower more patients to seek and receive the support they need from their healthcare providers, families and communities. “As a nurse for over 35 years, I have dedicated my life to helping people get the treatment and support they need to manage illness. HAE presents unique challenges because of the unpredictability of attacks and the lack of awareness of the condition,” said Barbara Mathews, RN and HAE Allies honoree. “In my role as a nurse I’ve had the privilege to partner with patients to help navigate some of these hurdles, hopefully enabling them to more easily work, travel, or participate in activities they enjoy. I have been truly awed by the optimism and tenacity of those facing this condition.” About HAE Hereditary angioedema (HAE) is a rare acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities, gastrointestinal tract, genitalia, and larynx. HAE is caused by low or dysfunctional levels of C1 esterase inhibitor (C1-INH), a naturally occurring molecule that inhibits plasma kallikrein, a key mediator of inflammation, and other serine proteases in the blood. HAE is estimated to affect up to 1 in 50,000 individuals. Learn more at www.HAEHope.com/HAEAllies. About KALBITOR KALBITOR is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. KALBITOR, which was discovered and developed by Dyax, is the first subcutaneous treatment available in the U.S. for treating acute HAE attacks.